Skip to main content
Grafa
Health
Amgen TEZSPIRE trial shows EoE improvements
Image for illustrative purposes only. Not a real photo.

Amgen TEZSPIRE trial shows EoE improvements

Share
  • Amgen and AstraZeneca reported positive Phase 3 results for TEZSPIRE in patients with eosinophilic esophagitis.
  • The CROSSING trial met both primary endpoints, showing improvements in tissue inflammation and swallowing symptoms.
  • The companies stated that results support continued evaluation of TEZSPIRE as a potential treatment option for EoE.

Amgen (NASDAQ:AMGN) and AstraZeneca (NYSE:AZN) reported positive Phase 3 results from the CROSSING trial of TEZSPIRE (tezepelumab-ekko), with the study meeting both primary endpoints in 368 patients with symptomatic eosinophilic esophagitis.

The randomized, double-blind trial compared TEZSPIRE administered every four weeks at two dose levels against placebo, with results at week 24 showing statistically significant improvements in histologic remission and swallowing symptom measures.

The companies reported that TEZSPIRE improved peak eosinophil counts in esophageal tissue and reduced the frequency and severity of swallowing difficulties measured through the Dysphagia Symptom Questionnaire, with benefits sustained through week 52.

Amgen and AstraZeneca developed TEZSPIRE as a targeted therapy that is already approved for severe asthma and chronic rhinosinusitis with nasal polyps, with the companies evaluating additional uses.

The CROSSING trial included patients aged 12–80 years with symptomatic, histologically active eosinophilic esophagitis, and the companies stated that the safety profile remained generally consistent with previously approved TEZSPIRE indications.

Frequently asked questions